Skip to main content
OpenTrials
Completed

NCT Number: NCT04261686

Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft

The objective of this study is to collect post-market, real-world safety and effectiveness data of the COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Arteriovenous Fistula Arteriovenous Malformations Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Fistula Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Vascular Diseases Vascular Fistula Vascular Malformations

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Arizona Kidney Disease and Hypertension Center Medical Research Services, Phoenix, Arizona, United States

Loading trial locations.

About this study

Prospective, multi-center, non-randomized clinical study designed to assess the long-term safety and effectiveness of the COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the AV access circuit of hemodialysis subjects dialyzing with an arteriovenous (AV) fistula.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Clinical Inclusion Criteria

  • Subject must voluntarily sign and date the Informed Consent Form (ICF) prior to collection of study data or performance of study procedures.
  • Subject must be either a male or non-pregnant female ≥ 21 years of age with an expected lifespan sufficient to allow for completion of all study procedures.
  • Subject must be willing to comply with the protocol requirements, including clinical and telephone follow-up.
  • Subject must have an upper extremity AV fistula that has undergone at least one successful dialysis session with two-needle cannulation, prior to the index procedure.
  • Subject must have angiographic evidence of a stenosis ≥ 50% (by visual estimation) located in the venous outflow of the AV access circuit and present with clinical or hemodynamic evidence of AV fistula dysfunction.
  • The target lesion must be ≤ 9cm in length. Note: multiple stenoses may exist within the target lesion.
  • The reference vessel diameter of the adjacent non-stenotic vein must be between 5.0 and 9.0mm.

Exclusion criteria

Clinical Exclusion Criteria

  • The subject is dialyzing with an AV graft.
  • The target lesion has had a corresponding thrombosis treated within 7 days prior to the index procedure.
  • The hemodialysis access is located in the lower extremity.
  • The subject has an infected AV fistula or uncontrolled systemic infection.
  • The subject has a known uncontrolled blood coagulation/bleeding disorder.
  • The subject has a known allergy or hypersensitivity to contrast media which cannot be adequately pre-medicated.
  • The subject has a known hypersensitivity to nickel-titanium (Nitinol) or tantalum.
  • The subject has another medical condition, which, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.
  • The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies.
  • Additional stenotic lesions (≥ 50%) in the venous outflow that are > 3cm from the edge of the target lesion and are not successfully treated (defined as ≤ 30% residual stenosis) prior to treating the target lesion.
  • An aneurysm or pseudoaneurysm is present within the target lesion.
  • The location of the target lesion would require the COVERATM Vascular Covered Stent be deployed across the elbow joint.
  • The target lesion is located within a stent.
  • The location of the target lesion would require that the COVERA™ Vascular Covered Stent be deployed at or across the segment of fistula utilized for dialysis needle puncture (i.e., "cannulation zone").
  • The location of the target lesion would require that the COVERA™ Vascular Covered Stent be placed in the central veins (subclavian, brachiocephalic, Superior Vena Cava (SVC)) or under the clavicle at the thoracic outlet.
  • There is incomplete expansion of an appropriately sized angioplasty balloon to its expected profile, in the operator's judgment, during primary angioplasty at the target lesion.

Treatment and study plan

Covera Vascular Covered Stent

Device

This is a single-arm study. All subjects will receive the Covera Vascular Covered Stent

Primary outcomes

  1. Safety through 30 days

    Time frame: Through 30 days following index procedure

    Freedom from any adverse event(s), localized or systemic, that reasonably suggest the involvement of the AV access circuit that require or result in any of the following alone or in combination: additional interventions, in-patient hospitalization or prolongation of an existing hospitalization; or death.

  2. Target Lesion Primary Patency (TLPP)

    Time frame: 1, 3, 6, 12, 18, 24, and 36 months following post-index procedure

    The interval following the index intervention until the next clinically driven reintervention at or adjacent to the original treatment site, or until the extremity is abandoned for permanent access.

  3. Access Circuit Primary Patency (ACPP)

    Time frame: 1, 3, 6, 12, 18, 24, and 36 months post index procedure

    The interval following the index intervention until the next access thrombosis or repeated intervention.

  4. Rate of Device and Procedure Related Adverse Events involving the access circuit

    Time frame: 1, 3, 6, 12, 18, 24, and 36 months post index procedure.

    Rate of device and procedure related adverse events (AEs) involving the access circuit.

  5. Total Number of Arteriovenous (AV) Access Circuit Reinterventions

    Time frame: 1, 3, 6, 12, 18, 24, and 36 months post index procedure

    Number of reinterventions to the arteriovenous (AV) access circuit until access abandonment or through study completion.

  6. Total Number of Target Lesion Reinterventions

    Time frame: 1, 3, 6, 12, 18, 24, and 36 months post index procedure

    Number of reinterventions to maintain target lesion patency

  7. Index of Patency Function (IPF)

    Time frame: 1, 3, 6, 12, 18, 24, and 36 months post index procedure

    Time from the index study procedure to study completion or access abandonment divided by the number of visits for a reintervention performed on the arteriovenous (AV) access circuit in order to maintain vascular access for hemodialysis.

  8. Index of Patency Function for Target Lesion

    Time frame: 1, 3, 6, 12, 18, 24, and 36 months post index procedure

    Time from the index study procedure to study completion or complete access abandonment divided by the number of visits for a reintervention performed at the target lesion in order to maintain vascular access for hemodialysis.

  9. Post-Intervention Secondary Patency

    Time frame: 1, 3, 6, 12, 18, 24, and 36 months post index procedure

    The interval after the index intervention until the access is abandoned.

  10. Acute Technical Success for Stent Graft Placement

    Time frame: At time of index procedure

    Defined as the successful deployment, based on the operator's opinion, of the implant to the intended location assessed at the time of the index procedure.

  11. Acute Procedural Success

    Time frame: At time of index procedure

    Defined as anatomic success and resolution of the pre-procedural clinical indicator(s) (clinical success) of a hemodynamically significant stenosis

Sponsors and collaborators

Lead sponsor

C. R. Bard

Industry

Registry information

Official study title

A Prospective, Multi-Center, Non-Randomized Clinical Study of the BARD® COVERA Arteriovenous (AV) Stent Graft in the Treatment of Stenosis in the Venous Outflow of AV Fistula Access Circuits (AVeNEW) Post Approval Study

Important dates

Study start
2020
Primary completion
2025
Study completion
2025
First posted
Feb 10, 2020
Registry last updated
Dec 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.